Premium
Treatment of monomorphic B‐cell lymphoma with rituximab after liver transplantation in a child
Author(s) -
Bueno Javier,
Ramil Carmen,
Somoza Ivan,
SanchezGalindo Amelia,
Solar Alfonso,
Arnal Francisco,
Alvarez Augusto,
SánchezMozo Pilar,
Gómez Manuel
Publication year - 2003
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1034/j.1399-3046.2003.00024.x
Subject(s) - rituximab , medicine , post transplant lymphoproliferative disorder , immunosuppression , lymphoma , lymphoproliferative disorders , cd20 , liver transplantation , b cell lymphoma , transplantation , monoclonal , immunology , monoclonal antibody , b cell , antibody
Rituximab, a monoclonal antibody directed against the B‐cell specific CD20 antigen has been used with success in post‐transplant lymphoproliferative disorder (PTLD) of B‐cell phenotype. However, the use of such drug in children with liver transplantation and PTLD is very limited. We report a 2‐yr‐old liver transplant recipient with monomorphic non‐Hodgkin lymphoma of B‐cell origin. The lymphoma did not respond to immunosuppression withdrawal, with a subsequent allograft rejection. Despite resumption of immunosuppression and rejection treatment, the lymphoma was successfully treated with rituximab.